What is Ultragenyx Pharmaceutical's other investing?

Ultragenyx Pharmaceutical (RARE) reported other investing of $0 in Q1 2026.

How has Ultragenyx Pharmaceutical's other investing changed year-over-year?

Ultragenyx Pharmaceutical's other investing decreased by 100.0% year-over-year, from $1M to $0.

What does other investing mean?

Miscellaneous investing cash flows not classified in specific line items.

Ultragenyx Pharmaceutical RARE Other Investing

Other Investing at other companies

Eli LillyLLY

$31M+128%

AmgenAMGN

$4M-88.9%

Taysha Gene Therapies, Inc.TSHA

-$3K-9.1%

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.87B-39.4%

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromOtherInvestingActivities.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's other investing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's other investing?: Ultragenyx Pharmaceutical (RARE) reported other investing of $0 in Q1 2026.
How has Ultragenyx Pharmaceutical's other investing changed year-over-year?: Ultragenyx Pharmaceutical's other investing decreased by 100.0% year-over-year, from $1M to $0.
What does other investing mean?: Miscellaneous investing cash flows not classified in specific line items.